• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » Effectiveness of Lithium in Children

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

Effectiveness of Lithium in Children

May 24, 2019
Lithium’s effectiveness for mania in children is surprisingly robust. The Collaborative Lithium Trials, which is the largest double-blind placebo-controlled study to date, found lithium to be both effective and well tolerated in patients ages 7-17 with bipolar disorder (Findling et al, Pediatrics 2015; 136 (5):885-894).

For bipolar disorder, lithium is typically used when other mood stabilizers—such as valproate, carbamazepine, and lamotrigine—have not been helpful, and after failed neuroleptic trials with medications, such as risperidone and aripiprazole. Lithium is also employed in depressive disorders after adequate trials of two or three antidepressants.

Before starting lithium, consider reducing or eliminating possible medications that might aggravate the condition; such as antidepressants, if there is mood instability; stimulants, if there is sleep disturbance; and benzodiazepines, if there is withdrawal agitation (you may need to go very slowly with reducing benzodiazepines). Once you’ve made these adjustments, start lithium using the gradual approach described here.

Before starting lithium, you should order baseline studies, including a complete blood count with differential; a comprehensive metabolic profile, including creatinine and blood urea nitrogen; thyroid stimulating hormone and thyroxine levels; and an EKG. After completing the baseline studies, consider the following:

  • In young children, a reasonable starting dose might be 150 mg at night, followed by a trough level after about 5 days, taken 8-12 hours after the dose. The target blood level range should be 0.8-1.2 mEq/L. Dosage increases of 150 mg can be done week by week with serial trough blood tests to check the level.

  • To try and get more even 24-hour coverage (half-life of lithium is 18-36 hours, with an average being 24 hours), dosing is typically increased by adding a morning dose, then an evening dose and so forth.

  • If possible, it is always wiser to use lower doses. If the child’s behavior and symptoms stabilize at a lower level, there is then no need to increase the dose to achieve the 0.8–1.2 target range.
    For children 13 and older, a starting dosage of 300 mg and dosage increments of 300 mg are more efficient, with the same target trough level.

  • All patients should be formally assessed and monitored at least every six months for abnormal involuntary movements. The Abnormal Involuntary Movement Scale (AIMS) works well. Some children cannot cooperate with this test, and so clinical observation and history from collateral sources (parents, teachers, etc.) must suffice.


Subscribers can read the full article in The Carlat Child Psychiatry Report, which includes advice on how to talk with parents about the decision to use lithium with their children. Not a subscriber? Join here.
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.